Apollomics
An innovative biopharmaceutical company committed to the discovery and development of oncology combination therapies.
Launch date
Employees
Market cap
€13.6m
Enterprise valuation
(€6m) (Public information from Sep 2024)
Share price
$0.127 APLM
Pleasanton California (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | - | - | - | - | <1m | 1.0m | - |
% growth | - | - | - | - | - | 100 % | - |
EBITDA | (73.5m) | (91.1m) | (239m) | (174m) | (42.1m) | (76.6m) | (127m) |
% EBITDA margin | - | - | - | - | (8420 %) | (7660 %) | - |
Profit | (74.8m) | (94.8m) | (241m) | (173m) | (65.3m) | (94.7m) | (145m) |
% profit margin | - | - | - | - | (13052 %) | (9470 %) | - |
EV / revenue | - | - | - | - | 26.4x | 38.1x | - |
EV / EBITDA | - | -1.4x | -0.6x | -0.5x | -0.3x | -0.5x | -0.3x |
R&D budget | 31.4m | 35.6m | 35.5m | 34.2m | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- |
| N/A | - |
N/A | $5.0m | Seed | |
N/A | Spinout | ||
$9.8m | Series A | ||
$100m | Series B | ||
* | $124m | Series C | |
* | $104m Valuation: $899m -9.9x EV/LTM EBITDA | SPAC IPO | |
* | N/A | $23.7m | Post IPO Equity |
* | N/A | $6.0m | Private Placement VC |
Total Funding | €223m |
Recent News about Apollomics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.